EUROATLANTIC-AIRWAYS
17.4.2024 09:01:28 CEST | Business Wire | Press release
euroAtlantic Airways – Transportes Aereos S.A. (“euroAtlantic”, “EAA” or “the Company”), the Portuguese aircraft wet-leasing and charter business, today announces that Stewart Higginson has been appointed CEO and Chair of euroAtlantic and will be joined by the highly experienced management team of Mário Alvim, Lourenço Gomes and João Nunes, who will complete the Board.
Alongside the Board changes, Njord I-Jet Aviation S.A.R.L ("Njord I-Jet"), which owns a controlling interest in EAA, has committed further funding to the Company, demonstrating Njord I-Jet’s confidence in the positive outlook for the business and positioning EAA for growth as it enters the next important phase in its development. The management team’s focus will be on optimising performance improvements and expanding the Company’s current fleet of five Boeing aircraft to meet demand and improving its market-leading ACMI and charter services.
Stewart has deep experience of delivering operational performance improvements in companies across multiple sectors. He has been an Operating Partner with Njord Partners since February 2015, during which time he has held a number of key leadership roles including CEO of Geoquip Marine and CEO of Nuova Deroma, and has held a number of board roles as both a director and Chair. Stewart has received multiple awards and nominations for his instrumental roles in corporate restructurings and turnarounds, including International Turnaround of the Year for DeepOcean in 2012, and for Solidal in 2020. Stewart was a Director at Alix Partners for nine years and is a member of the UK Institute for Turnaround.
Mário, Lourenço and João collectively have more than 40 years’ experience at euroAtlantic and c. 100 years of experience in the aviation industry. Mário is euroAtlantic’s Chief Pilot and has been at the Company since its founding year (1993). He started his career at Air Atlantis. Lourenço is Chief Operations Officer. He joined the Company in March 2016, having previously held management positions at TAP. He started his career as a pilot for Portugalia Airlines, TAP Portugal and Emirates. João rejoined euroAtlantic in March 2023, after having previously worked for euroAtlantic between 2004 and 2008 and holds the role of Accountable Manager. His 25+ year career in aviation includes experienced roles at TAP, Netjets and JetCapitalAviation, where he was Airworthiness Manager and Deputy Accountable Manager.
Njord I-Jet is wholly owned by funds managed by Njord Partners LLP, a long-term investor in the Western European middle-market with significant and proven expertise in successful turnarounds. Njord Partners has assets under management in excess of €1 billion, providing capital solutions and actively facilitating strategic and operational enhancements within its portfolio companies to drive value for all stakeholders.
Stewart Higginson, euroAtlantic CEO and Chair, commented: “I am delighted to be joining euroAtlantic, where I look forward to working with the new Board to drive the next phase of euroAtlantic’s growth and deliver a world-class ACMI and charter solutions business.”
Jakob Kjellberg, Co-Founder and Co-Portfolio Manager at Njord Partners, said: “We are excited about the future prospects of well capitalized EAA under new leadership. The Company couldn’t have anyone better than Stewart and the team to lead it through its ongoing transformation and deliver high quality, cost effective and flexible services to our valued customers. Stewart’s experience in optimising operations and performance is second-to-none and we know the business will thrive with him in this new role.”
About euroAtlantic Airways
euroAtlantic Airways is a Portuguese airline specializing in ACMI and charter solutions, operating a diverse fleet of aircraft. Headquartered in Carnaxide and based at Lisbon Airport, it offers charter services, wet-lease, and Ad-Hoc flights across the globe, and has served 719 Airports in 176 countries in 30 years of operations. euroAtlantic Airways was acquired a consortium including Njord Partners, in November 2019.
To find out more visit: https://www.euroatlantic.pt/en/quem-somos/
About Njord Partners
Njord Partners is a European special situations investment manager and provider of long-term flexible capital solutions, primarily to family-owned businesses. Established in 2013, Njord Partners has invested in 24 businesses and manages capital in excess of €1 billion. The Njord team has led turnarounds of over 25 companies located in 9 different jurisdictions, spanning 8 separate industries.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417583477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom